Where is YolTech located?

YolTech is headquartered in Shanghai, China.

Who is the current CEO of YolTech?

Yuxuan Wu of YolTech. They have also founded 1 company.

Is YolTech a funded company?

YolTech is a funded company, having raised a total of $133M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of YolTech?

YolTech's latest funding was a $***** Series C round on May 29, 2026, with participation from 6 investors. Its primary sector is Metabolic Diseases. In China, the Metabolic Diseases sector has seen $370M in funding in 2026 to date.

Where does YolTech rank among its competitors?

YolTech ranks 133rd amongst 1319 active competitors, of which 467 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of YolTech?

YolTech's top competitors include Alnylam, Forge Biologics and Strand Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

YolTech - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of gene editing and LNP delivery platforms for therapeutics. It focuses on creating novel tools for genome editing using metagenomics data. It develops in vivo gene-editing medicines for genetic, metabolic, cancer, and cardiovascular diseases. It is researching treatments for diseases such as familial hypercholesterolemia and hereditary transthyretin amyloidosis.

Website: www.yoltx.com/
Email ID: *****@yoltx.com
Phone Number: +86 **********

Key Metrics

Founded Year

2021

Location

Shanghai, China

Stage

Series C

Total Funding

$133M in 5 rounds

Latest Funding Round

Series C, May 29, 2026, $*****

Investors

Decheng Capital & 11 more

Ranked

133^rd among 1319 active competitors

Similar Companies

Alnylam & 1595 more

View YolTech's full profile

YolTech has raised a total funding of $133M over 5 rounds. Its latest funding round was a Series C round on May 29, 2026 for $*****. 6 investors participated in its latest round. YolTech has 12 institutional investors.

Here is the list of recent funding rounds of YolTech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 29, 2026	3418296	Series C	5635610	6625295	7297954	9135504
Sep 11, 2025	9681109	Series B	7910895	4450610	5606794	AstraZeneca
Nov 30, 2023	5473962	Series A	2616321	3696774	Decheng Capital	Guangzhou Industrial Investment Group & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of YolTech's funding rounds and investors

The founders of YolTech is Yuxuan Wu. Yuxuan Wu is the CEO of YolTech.

Here are the details of YolTech's key team members:

Yuxuan Wu: Founder & CEO of YolTech.

View details of YolTech's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of YolTech include Alnylam, Forge Biologics and Strand Therapeutics. Here is the list of Top 10 competitors of YolTech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 14 others	81/100
2nd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	72/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
4th	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Longitude Capital, Fairmount Funds Management ... & 3 others	71/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	69/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	69/100
7th	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Canaan & 18 others	69/100
8th	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	69/100
9th	Stoke Therapeutics 2014, Bedford (United States), Public	Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing	$131M	RTW Investments, Apple Tree Partners & 5 others	68/100
10th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of genome editing therapeutics using CRISPR and Cas9 technology	$85M	Atlas Venture, Novartis & 10 others	68/100
133rd	YolTech 2021, Shanghai (China), Series C	Developer of gene editing and LNP delivery platforms for therapeutics	$133M	Decheng Capital, Loayal Valley Capital & 10 others	56/100